Drugmaker Boehringer Ingelheim announced that early data on its experimental drug idarucizumab has shown that it effectively reverses the effects of the company’s blood thinner Pradaxa in a late-stage study. Pradaxa was the first drug in a new line of anticoagulants designed to replace the long-used warfarin for the prevention of blood clots in patients with the common heart rhythm abnormality known as atrial fibrillation. The drug hit blockbuster status quickly, but sales slowed when reports of major bleeding events began to mount. Unlike warfarin, there is no antidote to revers the blood thinning effects of Pradaxa. Pradaxa’s entrée to ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.